{"product_id":"dermatologic-principles-and-practice-in-oncology-9780470621882","title":"Dermatologic Principles and Practice in Oncology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis is the first book to focus on frequent and frequently disabling side effects involving the skin, hair, and nails in cancer patients.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of Contributors, vii\u003c\/p\u003e \u003cp\u003ePreface, x\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 Dermatology and Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Epidemiology and Burden of Disease, 3\u003cbr\u003e\u003ci\u003eBeth N. McLellan, Devika Patel and Mario E. Lacouture\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 The History of Supportive Oncodermatology, 17\u003cbr\u003e\u003ci\u003eYevgeniy Balagula, Steven T. Rosen and Mario E. Lacouture\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Structure and Function of the Integumentary System and the Dermatology Lexicon, 24\u003cbr\u003e\u003ci\u003eEmmy Graber and Amit Garg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Types of Dermatologic Reactions, 33\u003cbr\u003e\u003ci\u003eRaed O. Alhusayen, Sandra R. Knowles and Neil H. Shear\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0, 47\u003cbr\u003e\u003ci\u003eAlice Chen, Asha Acharya and Ann Setser\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health-Related Quality of Life, and Special Considerations in Dermatologic Oncology, 60\u003cbr\u003e\u003ci\u003eLynne I. Wagner and David Cella\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Dermatopathology, 69\u003cbr\u003e\u003ci\u003eMolly A. Hinshaw and James L. Troy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Cancer-Related Dermatologic Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8 Paraneoplastic, Inherited Cancer Syndrome, and Environmental Carcinogen-Related Dermatoses, 77\u003cbr\u003e\u003ci\u003eCindy England Owen and Jeffrey P. Callen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3 Dermatologic Conditions During Cancer Therapy\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9 Oral Mucosal Complications of Cancer Therapy, 89\u003cbr\u003e\u003ci\u003eStephen T. Sonis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Hair Disorders Associated with Anticancer Agents, 100\u003cbr\u003e\u003ci\u003eCaroline Yeager and Elise A. Olsen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Nail Abnormalities in Oncology Practice, 115\u003cbr\u003e\u003ci\u003eRobert Baran, Bernard Fouilloux and Caroline Robert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Pruritus, 122\u003cbr\u003e\u003ci\u003eTejesh Patel and Gil Yosipovitch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Management Options for Hot Flashes in Cancer Patients, 131\u003cbr\u003e\u003ci\u003eAmanda R. Moraska and Charles L. Loprinzi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 4 Skin Toxicities to Chemotherapy\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14 Alkylating Agents, 147\u003cbr\u003e\u003ci\u003eElisabeth Livingstone, Lisa Zimmer, Larissa Leister and Dirk Schadendorf\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Antimetabolite Reactions, 160\u003cbr\u003e\u003ci\u003eEmily Y. Chu and Heidi H. Kong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Topoisomerase-Interacting Agents, 170\u003cbr\u003e\u003ci\u003eTomas Skacel, Roger von Moos and Reinhard Dummer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Epidermal Growth Factor Receptor Inhibitor Reactions, 184\u003cbr\u003e\u003ci\u003eYevgeniy Balagula and Mario E. Lacouture\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Small Molecule Multikinase Inhibitors, 196\u003cbr\u003e\u003ci\u003eCaroline Robert, Vincent Sibaud and Christine Mateus\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Antimicrotubule Agents, 208\u003cbr\u003e\u003ci\u003eClaus Garbe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Histone Deacetylase Inhibitors, Proteasome Inhibitors, Demethylating Agents, Arsenicals, and Retinoids, 215\u003cbr\u003e\u003ci\u003eNajla Al-Dawsari, Shannon C. Trotter and Francine Foss\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Miscellaneous Reactions, 224\u003cbr\u003e\u003ci\u003eKatharina C. Kaehler, Christine B. Boers-Doets, \u003c\/i\u003e\u003ci\u003eMario E. Lacouture and Axel Hauschild\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Skin Toxicities due to Biotherapy, 233\u003cbr\u003e\u003ci\u003eKathryn T. Ciccolini, Katharina C. Kaehler, Mario E. Lacouture and Axel Hauschild\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Monoclonal Antibodies, 241\u003cbr\u003e\u003ci\u003eCaroline Robert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Endocrine Agents, 248\u003cbr\u003e\u003ci\u003eKatherine Szyfelbein Masterpol, Maura Dickler and Mario E. Lacouture\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Agents for the Management of Hematologic Reactions, 257\u003cbr\u003e\u003ci\u003eMee-young Lee and Caroline C. Kim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Radiation-Induced Skin Reactions, 264\u003cbr\u003e\u003ci\u003eRebecca K.S. Wong and Zahra Kassam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease, 281\u003cbr\u003e\u003ci\u003eStephanie W. Hu and Jonathan Cotliar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Extravasation Reactions, 295\u003cbr\u003e\u003ci\u003eSeppo W. Langer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Topical Anticancer Therapies, 301\u003cbr\u003e\u003ci\u003ePatricia L. Myskowski\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Life-threatening (Serious) Dermatologic Adverse Events, 310\u003cbr\u003e\u003ci\u003eMilan J. Anadkat\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Dermatologic Infections, 319\u003cbr\u003e\u003ci\u003eYevgeniy Balagula, Mario E. Lacouture and James I. Ito\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 5 Late Cutaneous Events from Cancer Treatment\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e32 Late Dermatologic Conditions, 339\u003cbr\u003e\u003ci\u003eJennifer Nam Choi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 6 Dermatologic Practice in Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e33 Management Algorithms for Dermatologic Adverse Events, 367\u003cbr\u003e\u003ci\u003eAlyx Rosen, Iris Amitay-Laish and Mario E. Lacouture\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Dermatologic Therapeutics and Formulations, 384\u003cbr\u003e\u003ci\u003eJudy H. Borovicka, Jennifer R.S. Gordon, Ann Cameron Haley, Nicole E. Larsen and Dennis P. West\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Dermatologic Techniques and Procedures, 401\u003cbr\u003e\u003ci\u003eRobert Eilers Jr., Kishwer S. Nehal and Erica H. Lee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Appearance-Related Concerns in the Cancer Patient, 410\u003cbr\u003e\u003ci\u003eAmy J. Derick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 417\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49525382512983,"sku":"9780470621882","price":150.05,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470621882.jpg?v=1731860303","url":"https:\/\/bookcurl.com\/products\/dermatologic-principles-and-practice-in-oncology-9780470621882","provider":"Book Curl","version":"1.0","type":"link"}